# A Study About Safety and Efficacy of Pirfenidone to Treat Grade 2 or Grade3 Radiation-induced Lung Injury.

> **NCT03902509** · PHASE2 · COMPLETED · sponsor: **Beijing Continent Pharmaceutical Co, Ltd.** · enrollment: 126 (actual)

## Conditions studied

- Radiation-induced Lung Injury

## Interventions

- **DRUG:** Pirfenidone
- **DRUG:** basic treatment

## Key facts

- **NCT ID:** NCT03902509
- **Lead sponsor:** Beijing Continent Pharmaceutical Co, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-24
- **Primary completion:** 2023-12-04
- **Final completion:** 2023-12-04
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2025-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03902509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03902509, "A Study About Safety and Efficacy of Pirfenidone to Treat Grade 2 or Grade3 Radiation-induced Lung Injury.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03902509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*